Ghrelin

Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

Retrieved on: 
Tuesday, October 12, 2021
Corporation, National Medical Products Administration, Nausea, Central nervous system, Cancer, Stomach, Moderately prosperous society, Netupitant, HPC, Hyperglycemia, Marketing, Growth, Internationalization, Vomiting, Human, Hyperuricemia, RNA, Large-cell lung carcinoma, Ghrelin, Heart, Precision medicine, Malignancy, Fosun Pharma, Hypertension, Group, Hyperlipidemia, Environment, Appetite, NEPA, Metabolism, Innovation, CINV, Integration, CEO, Patient, Research, Sustainable development, PONV, Pharmaceutical industry, Fine chemical, Platinum

Wu Yifang, Chairman and CEO of Fosun Pharma, commented: We are very pleased to sign this agreement with Helsinn.

Key Points: 
  • Wu Yifang, Chairman and CEO of Fosun Pharma, commented: We are very pleased to sign this agreement with Helsinn.
  • At Fosun, we are passionate about providing better health solutions for patients and these exclusive license and distribution agreements for Aloxi, Akynzeo and anamorelin across Mainland China, Hong Kong SAR and Macau SAR show our commitment to that mission.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) is a leading global pharmaceutical and healthcare provider in China.
  • Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry.

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Peptide hormones, Organ systems, Hormones, Communication, Forward-looking statement, Ghrelin, Amyotrophic lateral sclerosis

It is also licensed to Consilient Health Ltd. for the European Economic Area and United Kingdom, and Megapharm Ltd. for Israel and the Palestinian Authority.

Key Points: 
  • It is also licensed to Consilient Health Ltd. for the European Economic Area and United Kingdom, and Megapharm Ltd. for Israel and the Palestinian Authority.
  • Its level is often reduced in ALS patients and stimulation of GH excretion improves survival in ALS mouse models.
  • Dr. Steyn\xe2\x80\x99s research team at The University have confirmed these positive effects of ghrelin mimetics in several experiments.
  • Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements.

Global Cancer Anorexia Market Outlook to 2030: Epidemiology, Drugs, Unmet Needs, Pipeline & Development Activities, Competition

Retrieved on: 
Monday, April 12, 2021
Medical specialties, Clinical medicine, Medicine, Appetite stimulants, Obesity, Neuropeptides, Peptide hormones, Rehabilitation medicine, Anamorelin, Ghrelin, Cachexia, Appetite

Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite, and metabolism.

Key Points: 
  • Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite, and metabolism.
  • Anamorelin has shown effects in increasing body weight and muscle mass, as well as appetite in patients with cancer cachexia.
  • Moreover, the emerging pipeline of cancer anorexia is quite weak, with three promising lead candidates in the late and early stages of development.
  • They will require few years to be investigated and launched in the market as potential therapeutic treatment options for cancer anorexia.\n5 Disease Background and Overview: Cancer Anorexia\n'

AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY

Retrieved on: 
Thursday, June 25, 2020
Endocrine system, Organ systems, Hormones, Peptide hormones, Growth hormones, Neuroendocrinology, Indoles, Peptides, Macimorelin, Growth hormone, Pituitary gland, Ghrelin

Miron Drucker, CEO of Megapharm, said, Macimorelin has demonstrated potential in assessing growth hormone deficiencies in both adults and children.

Key Points: 
  • Miron Drucker, CEO of Megapharm, said, Macimorelin has demonstrated potential in assessing growth hormone deficiencies in both adults and children.
  • We are proud to establish this agreement with Aeterna Zentaris to bring macimorelin to Israel and the Palestinian Authority.
  • Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone from the pituitary gland.
  • In January 2019, the European Commission granted marketing authorization for macimorelin to Aeterna Zentaris for diagnosis of growth hormone deficiency in adults.

AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN

Retrieved on: 
Tuesday, April 7, 2020
Endocrine system, Organ systems, Hormones, Growth hormones, Peptide hormones, Peptides, Indoles, Formamides, Macimorelin, Growth hormone, Ghrelin, Pituitary gland

This represents a very exciting advancement for our pediatric development program, commented, Dr.Nicola Ammer , Chief Medical Officer of Aeterna Zentaris.

Key Points: 
  • This represents a very exciting advancement for our pediatric development program, commented, Dr.Nicola Ammer , Chief Medical Officer of Aeterna Zentaris.
  • Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone from the pituitary gland.
  • In January 2019, the European Commission granted marketing authorization for macimorelin to Aeterna Zentaris for diagnosis of growth hormone deficiency in adults.
  • Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, Drugs, Chemistry, Peptides, Peptide hormones, Appetite stimulants, G protein-coupled receptors, Growth hormone secretagogue, Protein families, Ghrelin, Growth hormone, Signaling peptide receptor

The "Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin.
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 19 molecules.
  • The latest report Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.